Persistence of inflammatory and vascular mediators 5 months after hospitalization with COVID-19 infection
Melhorn J. et al, (2023), Frontiers in Medicine, 10
Constructing custom-made radiotranscriptomic signatures of vascular inflammation from routine CT angiograms: a prospective outcomes validation study in COVID-19
Kotanidis CP. et al, (2022), The Lancet Digital Health, 4, e705 - e716
Combination fixed-dose β agonist and steroid inhaler as required for adults or children with mild asthma: a Cochrane systematic review
Crossingham I. et al, (2022), BMJ Evidence-Based Medicine, 27, 178 - 184
Divergent trajectories of antiviral memory after SARS-CoV-2 infection
Tomic A. et al, (2022), Nature Communications, 13
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
Ahern DJ. et al, (2022), Cell, 185, 916 - 938.e58
An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease
Peng Y. et al, (2022), Nature Immunology, 23, 50 - 61
Persistence of inflammatory and vascular damage mediators 5 months after acute COVID-19
Petousi N. et al, (2022), EUROPEAN RESPIRATORY JOURNAL, 60
Spontaneous pneumomediastinum, subcutaneous emphysema and pneumothorax in non-intubated patients with COVID-19 pneumonitis: a retrospective case note review of a single centre experience
Karwal R. et al, (2022), EUROPEAN RESPIRATORY JOURNAL, 60
Improved COVID-19 outcomes in a large non-invasive respiratory support cohort despite emergence of the alpha variant
Turnbull CD. et al, (2021), BMJ Open Respiratory Research, 8, e001044 - e001044
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
Skelly DT. et al, (2021), Nature Communications, 12
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
Ahern DJ. et al, (2021)
Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma
Crossingham I. et al, (2021), Cochrane Database of Systematic Reviews, 2021
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Abaleke E. et al, (2021), The Lancet, 397, 605 - 612
COMBINATION FIXED-DOSE BETA AGONIST AND STEROID INHALER AS REQUIRED FOR ADULTS OR CHILDREN WITH MILD ASTHMA: A COCHRANE SYSTEMATIC REVIEW
Fries A. et al, (2021), THORAX, 76, A24 - A24
EVALUATION OF MYCOBACTERIUM TUBERCULOSIS-SPECIFIC IFN-G, TNF-A, CXCL10, IL2, CCL2, CCL7 AND CCL4 LEVELS FOR ACTIVE TUBERCULOSIS DIAGNOSIS
Fries A. et al, (2021), THORAX, 76, A27 - A28
Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma
Crossingham I. et al, (2020), Cochrane Database of Systematic Reviews
P170 Single centre experience on idiopathic pulmonary fibrosis patient tolerance of pirfenidone; impact on nurse-led ILD helpline usage
Rathnapala A. et al, (2016), Thorax, 71, A176.1 - A176
P175 Single centre experience of the real-life impact of pirfenidone on lung function in patients with idiopathic pulmonary fibrosis
Rathnapala A. et al, (2016), Thorax, 71, A179.1 - A179
S101 Single centre experience of switching patients with idiopathic pulmonary fibrosis from pirfenidone to nintedanib
Rathnapala A. et al, (2016), Thorax, 71, A60.1 - A60